Celon Pharma SA (8RP) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cpl409116 | Rheumatoid Arthritis | Phase II | Completed | Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis | May 04, 2022 | ― |
| Cpl500036 - Low Dose, Cpl500036 - High Dose | Parkinson Disease, Dyskinesia, Medication-Induced | Phase II | Completed | Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia | Feb 17, 2022 | ― |
| Cpl500036 - Low Dose, Cpl500036 - High Dose | Schizophrenia | Phase II | Completed | Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia | Feb 09, 2022 | ― |
| Cpl207280 | Type 2 Diabetes | Phase II | Unknown | Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes | Feb 04, 2022 | ― |
| Cpl409116 | Healthy | Phase I | Completed | Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers | Nov 27, 2020 | ― |
| Cpl207280, Metformin Hydrochloride 750 Mg | Healthy Volunteers | Phase I | Completed | Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers. | Nov 06, 2020 | ― |
| Cpl304110 | Endometrial Cancer, Bladder Cancer, Gastric Cancer, Sarcoma, Cholangiocarcinoma, Squamous Non-Small Cell Lung Cancer, Other Solid Tumours | Phase I | Recruiting | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Oct 31, 2019 | ― |
| Esketamine Dpi - Low Dose, Esketamine Dpi - Medium Dose, Esketamine Dpi - High Dose | Major Depressive Disorder | Phase II | Completed | Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression | May 21, 2019 | ― |
| Esketamine Dpi - Low Dose, Esketamine Dpi - Medium Dose, Esketamine Dpi - High Dose | Bipolar Depression | Phase II | Completed | Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression | May 21, 2019 | ― |
| Cpl500036 Compound | Healthy Volunteers | Phase I | Completed | Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers | Mar 11, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cpl409116 | Phase II | Rheumatoid Arthritis | Completed | Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis | May 04, 2022 | ― |
| Cpl500036 - Low Dose, Cpl500036 - High Dose | Phase II | Parkinson Disease, Dyskinesia, Medication-Induced | Completed | Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients with Levodopa Induced Dyskinesia | Feb 17, 2022 | ― |
| Cpl500036 - Low Dose, Cpl500036 - High Dose | Phase II | Schizophrenia | Completed | Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With Schizophrenia | Feb 09, 2022 | ― |
| Cpl207280 | Phase II | Type 2 Diabetes | Unknown | Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes | Feb 04, 2022 | ― |
| Cpl409116 | Phase I | Healthy | Completed | Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers | Nov 27, 2020 | ― |
| Cpl207280, Metformin Hydrochloride 750 Mg | Phase I | Healthy Volunteers | Completed | Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers. | Nov 06, 2020 | ― |
| Cpl304110 | Phase I | Endometrial Cancer, Bladder Cancer, Gastric Cancer, Sarcoma, Cholangiocarcinoma, Squamous Non-Small Cell Lung Cancer, Other Solid Tumours | Recruiting | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Oct 31, 2019 | ― |
| Esketamine Dpi - Low Dose, Esketamine Dpi - Medium Dose, Esketamine Dpi - High Dose | Phase II | Major Depressive Disorder | Completed | Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression | May 21, 2019 | ― |
| Esketamine Dpi - Low Dose, Esketamine Dpi - Medium Dose, Esketamine Dpi - High Dose | Phase II | Bipolar Depression | Completed | Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression | May 21, 2019 | ― |
| Cpl500036 Compound | Phase I | Healthy Volunteers | Completed | Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers | Mar 11, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Celon Pharma SA (DE:8RP) have in its pipeline
Celon Pharma SA DE:8RP is currently developing the following drugs: Cpl409116, Cpl500036 - Low Dose, Cpl500036 - High Dose, Cpl207280, Cpl207280, Metformin Hydrochloride 750 Mg, Cpl304110, Esketamine Dpi - Low Dose, Esketamine Dpi - Medium Dose, Esketamine Dpi - High Dose, Cpl500036 Compound, Esketamine Dpi. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
